Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Key Contacts
Latest press releases
Show me all press releasesPinsent Masons advises senior and equity bridge lenders on Khalifa University Student Accommodation public-private partnership project
Multinational law firm Pinsent Masons has advised HSBC, Korea Development Bank, The Norinchukin Bank, Intesa Sanpaolo, and Abu Dhabi Commercial Bank on all aspects of the project financing of the Khalifa University Student Accommodation public-private partnership (PPP) project.
Pinsent Masons appointed to draft new standard forms of building works contracts in Hong Kong
Multinational law firm Pinsent Masons has been appointed by The Hong Kong Institute of Architects, Hong Kong Institute of Construction Managers and The Hong Kong Institute of Surveyors to assist with the drafting of a new generation of the standard forms of building works contracts for Hong Kong last updated in 2005/2006.
Pinsent Masons advises SPE Capital in the sale of Amanys Pharma to Laprophan
Multinational law firm Pinsent Masons has assisted SPE Capital, an independent management firm, in the sale of Amanys Pharma to Laprophan, a pioneering pharmaceutical company in Morocco.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons hires senior litigation and investigations partner Melanie Ryan in London
Multinational law firm Pinsent Masons has appointed litigation partner Melanie Ryan to join its Global Investigations team in London.
Pinsent Masons advises Sandoz on acquisition of remaining shares in Rowex Joint Venture
Multinational law firm Pinsent Masons has advised Sandoz on the acquisition of the remaining shares in Rowex Limited, a joint venture in Ireland between Sandoz and Rowa Pharmaceuticals.
Pinsent Masons hires Life Science partner in Dublin
Multinational law firm Pinsent Masons has hired transactional life sciences specialist Michael Stewart as partner in its Dublin office as it expands its pan-European Technology, Science and Industry (TSI) capabilities.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]